Notably, Gal-3 has also been recently included in the American College of Cardiology Foundation (ACCF) and the American Heart Association (AHA) Guidelines for Management of Heart Failure, as an emerging biomarker for additive risk stratification in HF patients (10). The gene discussed is LGALS3; the disease is heart failure.